FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306407506> ?p ?o ?g. }

• W4306407506 endingPage "105445" @default.
• W4306407506 startingPage "105445" @default.
• W4306407506 abstract "The emergence and rapid spreading of SARS-CoV-2 variants of concern (VOCs) have posed a great challenge to the efficacy of vaccines and therapeutic antibodies, calling for antivirals that can overcome viral evasion. We recently reported that SARS-CoV-2 fusion-inhibitory lipopeptides, IPB02V3 and IPB24, possessed the potent activities against divergent VOCs, including Alpha, Beta, Gamma, Delta, and the initial Omicron strain (B.1.1.529); however, multiple Omicron sublineages have emerged and BA.4/5 is now becoming predominant globally. In this study, we focused on characterizing the functionality of the spike (S) proteins derived from Omicron sublineages and their susceptibility to the inhibition of IPB02V3 and IPB24. We first found that the S proteins of BA.2, BA.2.12.1, BA.3, and BA.4/5 exhibited significantly increased cell fusion capacities compared to BA.1, whereas the pseudoviruses of BA.2.12.1, BA.3, and BA.4/5 had significantly increased infectivity relative to BA.1 or BA.2. Next, we verified that IPB02V3 and IPB24 also maintained their very high potent activities in inhibiting diverse Omicron sublineages, even with enhanced potencies relative to the inhibition on ancestral virus. Moreover, we demonstrated that evolved Omicron mutations in the inhibitor-binding heptad repeat 1 (HR1) site could impair the S protein-driven cell fusogenicity and infectivity, but none of single or combined mutations affected the antiviral activity of IPB02V3 and IPB24. Therefore, we believe that viral fusion inhibitors possess high potential to be developed as effective drugs for fighting SARS-CoV-2 variants including diverse Omicron sublineages." @default.
• W4306407506 created "2022-10-17" @default.
• W4306407506 creator A5020524854 @default.
• W4306407506 creator A5025375416 @default.
• W4306407506 creator A5036881486 @default.
• W4306407506 creator A5056671511 @default.
• W4306407506 creator A5069273642 @default.
• W4306407506 date "2022-12-01" @default.
• W4306407506 modified "2023-10-15" @default.
• W4306407506 title "Potent inhibition of diverse Omicron sublineages by SARS-CoV-2 fusion-inhibitory lipopeptides" @default.
• W4306407506 cites W2072746903 @default.
• W4306407506 cites W2149512873 @default.
• W4306407506 cites W2312790603 @default.
• W4306407506 cites W2602879557 @default.
• W4306407506 cites W2730038812 @default.
• W4306407506 cites W2787830055 @default.
• W4306407506 cites W2807812400 @default.
• W4306407506 cites W2885114330 @default.
• W4306407506 cites W2913037262 @default.
• W4306407506 cites W2922433765 @default.
• W4306407506 cites W3007643904 @default.
• W4306407506 cites W3009335299 @default.
• W4306407506 cites W3014912119 @default.
• W4306407506 cites W3022735223 @default.
• W4306407506 cites W3039901154 @default.
• W4306407506 cites W3043431476 @default.
• W4306407506 cites W3136828643 @default.
• W4306407506 cites W3137469790 @default.
• W4306407506 cites W3138734145 @default.
• W4306407506 cites W3153244911 @default.
• W4306407506 cites W3165631371 @default.
• W4306407506 cites W3188318245 @default.
• W4306407506 cites W3199849883 @default.
• W4306407506 cites W3208696217 @default.
• W4306407506 cites W3215827060 @default.
• W4306407506 cites W3216478751 @default.
• W4306407506 cites W4200059599 @default.
• W4306407506 cites W4200625712 @default.
• W4306407506 cites W4206481051 @default.
• W4306407506 cites W4210360899 @default.
• W4306407506 cites W4220709353 @default.
• W4306407506 cites W4220724000 @default.
• W4306407506 cites W4220952200 @default.
• W4306407506 cites W4220970521 @default.
• W4306407506 cites W4225156805 @default.
• W4306407506 cites W4225266546 @default.
• W4306407506 cites W4282836344 @default.
• W4306407506 cites W4282980823 @default.
• W4306407506 cites W4283026725 @default.
• W4306407506 cites W4283322856 @default.
• W4306407506 cites W4283588867 @default.
• W4306407506 cites W4283704819 @default.
• W4306407506 cites W4283821020 @default.
• W4306407506 cites W4286220782 @default.
• W4306407506 doi "https://doi.org/10.1016/j.antiviral.2022.105445" @default.
• W4306407506 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36265805" @default.
• W4306407506 hasPublicationYear "2022" @default.
• W4306407506 type Work @default.
• W4306407506 citedByCount "7" @default.
• W4306407506 countsByYear W43064075062023 @default.
• W4306407506 crossrefType "journal-article" @default.
• W4306407506 hasAuthorship W4306407506A5020524854 @default.
• W4306407506 hasAuthorship W4306407506A5025375416 @default.
• W4306407506 hasAuthorship W4306407506A5036881486 @default.
• W4306407506 hasAuthorship W4306407506A5056671511 @default.
• W4306407506 hasAuthorship W4306407506A5069273642 @default.
• W4306407506 hasBestOaLocation W43064075061 @default.
• W4306407506 hasConcept C103038307 @default.
• W4306407506 hasConcept C104317684 @default.
• W4306407506 hasConcept C105702510 @default.
• W4306407506 hasConcept C106358424 @default.
• W4306407506 hasConcept C122146531 @default.
• W4306407506 hasConcept C159047783 @default.
• W4306407506 hasConcept C167625842 @default.
• W4306407506 hasConcept C169760540 @default.
• W4306407506 hasConcept C17077164 @default.
• W4306407506 hasConcept C185592680 @default.
• W4306407506 hasConcept C2522874641 @default.
• W4306407506 hasConcept C2778022156 @default.
• W4306407506 hasConcept C55493867 @default.
• W4306407506 hasConcept C86803240 @default.
• W4306407506 hasConceptScore W4306407506C103038307 @default.
• W4306407506 hasConceptScore W4306407506C104317684 @default.
• W4306407506 hasConceptScore W4306407506C105702510 @default.
• W4306407506 hasConceptScore W4306407506C106358424 @default.
• W4306407506 hasConceptScore W4306407506C122146531 @default.
• W4306407506 hasConceptScore W4306407506C159047783 @default.
• W4306407506 hasConceptScore W4306407506C167625842 @default.
• W4306407506 hasConceptScore W4306407506C169760540 @default.
• W4306407506 hasConceptScore W4306407506C17077164 @default.
• W4306407506 hasConceptScore W4306407506C185592680 @default.
• W4306407506 hasConceptScore W4306407506C2522874641 @default.
• W4306407506 hasConceptScore W4306407506C2778022156 @default.
• W4306407506 hasConceptScore W4306407506C55493867 @default.
• W4306407506 hasConceptScore W4306407506C86803240 @default.
• W4306407506 hasFunder F4320321001 @default.
• W4306407506 hasFunder F4320321849 @default.
• W4306407506 hasFunder F4320322392 @default.

• next